Lucas Montarce
Known title: EVP & CFOCIK: 0001752447
Lucas Montarce's purchase track record
Lucas Montarce has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/15/2025 | LLY | $495K | +46.4% | +48.8% | +6.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LLY | ▲ Buy | Option Exercise | 368 | $0 | 2/16/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 160 | $166K | 2/16/2026 | View on chart |
| LLY | ▲ Buy | Grant | 1,365 | $1.4M | 2/9/2026 | View on chart |
| LLY | ▲ Buy | Open Market | 715 | $495K | 8/15/2025 | View on chart |
| LLY | ▲ Buy | Grant | 2,896 | $2.5M | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 1,074 | $0 | 11/1/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 467 | $383K | 11/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.